Employers Are Quietly Redesigning Health Plans Around GLP-1s

A new report from Peterson Health Technology Institute quietly captures something many employers are only beginning to articulate: GLP-1 coverage is becoming one of the most consequential benefit design decisions of the decade.

Their recent analysis — Employer Approaches to GLP-1 Coverage: Market Trend Report — examines how companies are responding to the rapid adoption of medications like Semaglutide and Tirzepatide.

The tension is obvious.

Employees want access.
Clinicians see meaningful metabolic benefits.
But employers are confronting a new reality: pharmacy spend that can escalate unpredictably.

What’s striking about the report is not the cost discussion — that part is widely known.

It’s how employers are responding structurally.

Across the market, several patterns are emerging:

• Employers are moving away from open-ended GLP-1 coverage
• Coverage is increasingly tied to structured clinical programs
• Participation in nutrition or lifestyle support is becoming a prerequisite
• Employers are exploring outcomes-based contracting with vendors

In other words, the market is shifting from:

“Do we cover GLP-1s?”

to

“What clinical infrastructure should surround GLP-1 therapy?”

That shift matters.

Weight-loss medications are not simply another pharmacy benefit.
They force employers to think about metabolic health as a program, not a prescription.

The implications for benefits design are significant:

• clinical oversight becomes central
• program adherence matters
• long-term maintenance strategies become necessary
• employers start evaluating metabolic care vendors rather than simply pharmacy coverage

The most interesting question is not whether GLP-1 utilization will rise.

It will.

The real question is which models of care will make these therapies sustainable within employer health plans.

The companies that figure that out will shape the next phase of employer-sponsored healthcare.

Report from Peterson Health Technology Institute:
https://phti.org/wp-content/uploads/sites/3/2025/12/PHTI-Employer-Approaches-to-GLP-1-Coverage-Market-Trend-Report.pdf

Curious how others are seeing employers approach this. Are organizations moving toward structured metabolic programs, or still treating GLP-1s primarily as a pharmacy benefit?